Emanuel Petricoin

1.6k total citations · 1 hit paper
12 papers, 1.3k citations indexed

About

Emanuel Petricoin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Emanuel Petricoin has authored 12 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Emanuel Petricoin's work include Cancer Genomics and Diagnostics (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Advanced Biosensing Techniques and Applications (2 papers). Emanuel Petricoin is often cited by papers focused on Cancer Genomics and Diagnostics (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Advanced Biosensing Techniques and Applications (2 papers). Emanuel Petricoin collaborates with scholars based in United States, China and Italy. Emanuel Petricoin's co-authors include Christopher D. Benjamin, Andrew C. Larner, Michael David, Richard Pine, Michael J. Weber, Lance A. Liotta, Jianghong Deng, Peihua Gu, Joseph B. Margolick and Jiangbing Zhou and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Emanuel Petricoin

12 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

2007 539 citations Jiangbing Zhou, Julia Wulfkuhle et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Emanuel Petricoin

Since Specialization

Citations

This map shows the geographic impact of Emanuel Petricoin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emanuel Petricoin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emanuel Petricoin more than expected).

Fields of papers citing papers by Emanuel Petricoin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emanuel Petricoin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emanuel Petricoin. The network helps show where Emanuel Petricoin may publish in the future.

Co-authorship network of co-authors of Emanuel Petricoin

This figure shows the co-authorship network connecting the top 25 collaborators of Emanuel Petricoin. A scholar is included among the top collaborators of Emanuel Petricoin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emanuel Petricoin. Emanuel Petricoin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer 2021 ·Clinical Cancer Research ·Paula I. González-Ericsson, (unknown), Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng, Na Luo, Henry Gómez, Violeta Sánchez, Melinda E. Sanders, Lajos Pusztai, Emanuel Petricoin, Kim Blenman, Justin M. Balko, (unknown)	54
2	Cofilin hyperactivation in HIV infection and targeting the cofilin pathway using an anti-α ₄ β ₇ integrin antibody 2019 ·Science Advances ·Sijia He, Yajing Fu, Jia Guo, Mark Spear, Jiuling Yang, Benjamin Trinité, (unknown), Shuai Fu, Yongjun Jiang, Zining Zhang, Junjie Xu, Haibo Ding, David N. Levy, Wanjun Chen, Emanuel Petricoin, Lance A. Liotta, Hong Shang, Yuntao Wu	14
3	Multi-omic molecular comparison of primary versus metastatic pancreatic tumours 2019 ·British Journal of Cancer ·Gagandeep Brar, Edik M. Blais, R Joseph Bender, Jonathan R. Brody, Davendra Sohal, Subha Madhavan, Vincent J. Picozzi, Andrew Hendifar, Vincent Chung, (unknown), Sameh Mikhail, Lynn M. Matrisian, Lola Rahib, Emanuel Petricoin, Michael J. Pishvaian	23
4	Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial. 2019 ·Journal of Clinical Oncology ·Julia Wulfkuhle, Christina Yau, Denise M. Wolf, Rosa I. Gallagher, Lamorna Brown Swigart, Gillian L. Hirst, Michael J. Campbell, Rita Nanda, Minetta C. Liu, Lajos Pusztai, Laura J. Esserman, Donald A. Berry, Laura van ‘t Veer, Emanuel Petricoin, (unknown)	6
5	Induction of nerve growth factor by phorbol 12-myristate 13-acetate is dependent upon the mitogen activated protein kinase pathway 2018 ·Heliyon ·(unknown), Valerie Calvert, Steven A. Roberts, (unknown), Emanuel Petricoin, Robin D. Couch	5
6	Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma 2017 ·JCO Precision Oncology ·Richard Tuli, Simon S. Lo, (unknown), Michael J. Pishvaian, R Joseph Bender, Emanuel Petricoin, Jonathan R. Brody, Nicholas N. Nissen	10
7	A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative 2016 ·Oncotarget ·Michael J. Pishvaian, R Joseph Bender, Lynn M. Matrisian, Lola Rahib, Andrew Hendifar, William Hoos, (unknown), Vincent Chung, Vincent J. Picozzi, (unknown), Kimberly Mason, (unknown), (unknown), Subha Madhavan, Emanuel Petricoin, Jonathan R. Brody	49
8	Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL 2010 ·PLoS ONE ·Benedetta Accordi, Virginia Espina, Marco Giordan, Amy VanMeter, Gloria Milani, (unknown), Maria Ruzzene, Manuela Sciro, Luca Trentin, Ruggero De Maria, Geertruy te Kronnie, Emanuel Petricoin, Lance Liotta, Giuseppe Basso	40
9	Monitoring Proteins and Protein Networks Using Reverse Phase Protein Arrays 2010 ·Disease Markers ·Bridget S. Wilson, Lance A. Liotta, Emanuel Petricoin	25
10	Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) 2009 ·Journal of Clinical Oncology ·Laura J. Esserman, (unknown), Maggie C.U. Cheang, A. DeMichele, LA Carey, Laura van ‘t Veer, J. Gray, Emanuel Petricoin, Kathleen Conway, (unknown), D. A. Berry	14
11	Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance breakdown → 2007 ·Proceedings of the National Academy of Sciences ·Jiangbing Zhou, Julia Wulfkuhle, Hao Zhang, Peihua Gu, Yanqin Yang, Jianghong Deng, Joseph B. Margolick, Lance A. Liotta, Emanuel Petricoin, Ying Zhang	539
12	Requirement for MAP Kinase (ERK2) Activity in Interferon α- and Interferon β-Stimulated Gene Expression Through STAT Proteins 1995 ·Science ·Michael David, Emanuel Petricoin, Christopher D. Benjamin, Richard Pine, Michael J. Weber, Andrew C. Larner	492

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact